CN101835492B - 用于制药应用的热动力学混合 - Google Patents

用于制药应用的热动力学混合 Download PDF

Info

Publication number
CN101835492B
CN101835492B CN2008801123533A CN200880112353A CN101835492B CN 101835492 B CN101835492 B CN 101835492B CN 2008801123533 A CN2008801123533 A CN 2008801123533A CN 200880112353 A CN200880112353 A CN 200880112353A CN 101835492 B CN101835492 B CN 101835492B
Authority
CN
China
Prior art keywords
tkc
ktz
compositions
polymer
excipients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2008801123533A
Other languages
English (en)
Chinese (zh)
Other versions
CN101835492A (zh
Inventor
C·布拉夫
J·W·麦吉尼提
D·A·米勒
J·C·迪农齐奥
R·O·威廉姆斯三世
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Austin Pharmaceutical Co ltd
University of Texas System
Original Assignee
Integrated Composite Material Corp
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrated Composite Material Corp, University of Texas System filed Critical Integrated Composite Material Corp
Publication of CN101835492A publication Critical patent/CN101835492A/zh
Application granted granted Critical
Publication of CN101835492B publication Critical patent/CN101835492B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/07—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN2008801123533A 2007-08-21 2008-08-21 用于制药应用的热动力学混合 Active CN101835492B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95704407P 2007-08-21 2007-08-21
US60/957,044 2007-08-21
US5092208P 2008-05-06 2008-05-06
US61/050,922 2008-05-06
PCT/US2008/073913 WO2009026461A2 (en) 2007-08-21 2008-08-21 Thermo-kinetic mixing for pharmaceutical applications

Publications (2)

Publication Number Publication Date
CN101835492A CN101835492A (zh) 2010-09-15
CN101835492B true CN101835492B (zh) 2012-11-21

Family

ID=40378995

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801123533A Active CN101835492B (zh) 2007-08-21 2008-08-21 用于制药应用的热动力学混合

Country Status (6)

Country Link
US (6) US8486423B2 (enExample)
EP (1) EP2187968A4 (enExample)
JP (4) JP6073043B2 (enExample)
CN (1) CN101835492B (enExample)
CA (3) CA2990445C (enExample)
WO (1) WO2009026461A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246935B2 (en) 2016-05-13 2022-02-15 Merck Patent Gmbh Particle size and distribution of polymer for melt extrusion application

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687192C (en) 2007-06-04 2015-11-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
CA2990445C (en) * 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US9545361B1 (en) * 2011-07-25 2017-01-17 Dispersol Technologies, Llc Multiple speed process for preserving heat sensitive portions of a thermokinetically melt blended batch
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
JP2012501965A (ja) * 2008-06-16 2012-01-26 バインド バイオサイエンシズ インコーポレイテッド 薬剤を装填したポリマーナノ粒子及びその製造方法と使用方法
EP2309991B1 (en) 2008-06-16 2019-03-06 Pfizer Inc Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
CA2741862C (en) * 2008-10-31 2017-10-17 Mahmoud A. Elsohly Compositions containing delta-9-thc-amino acid esters and process of preparation
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
EP2379064B1 (en) * 2008-12-15 2020-02-26 Pfizer Inc. Long circulating nanoparticles for sustained release of therapeutic agents
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
WO2011072218A2 (en) 2009-12-11 2011-06-16 Bind Biosciences Stable formulations for lyophilizing therapeutic particles
ES2780156T3 (es) 2009-12-15 2020-08-24 Pfizer Composiciones terapéuticas de nanopartículas poliméricas con alta temperatura de transición vítrea o copolímeros de alto peso molecular
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
CN102204868B (zh) * 2011-05-18 2014-01-22 北京化工大学 采用多元辅料制备吲哚美辛速释制剂的热熔挤出工艺
US9821283B1 (en) * 2011-07-25 2017-11-21 Dispersol Technologies, Llc Direct probe sensed temperature method for speed change for heat sensitive portions of a thermokinetically melt blended batch
US9877923B2 (en) 2012-09-17 2018-01-30 Pfizer Inc. Process for preparing therapeutic nanoparticles
CA2935307C (en) 2013-12-31 2023-05-09 Ascendia Pharmaceuticals, Llc Pharmaceutical compositions for poorly water-soluble compounds
MX378984B (es) 2014-03-14 2025-03-11 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso.
WO2015141662A1 (ja) 2014-03-18 2015-09-24 武田薬品工業株式会社 固体分散体
HUE057232T2 (hu) * 2014-04-18 2022-04-28 Dispersol Technologies Llc Többsebességes eljárás és keverõ termokinetikusan ömlesztve elegyített sarzs hõérzékeny részeinek megõrzésére
WO2016073421A1 (en) * 2014-11-03 2016-05-12 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same
CN107205935A (zh) * 2015-01-20 2017-09-26 默克专利股份有限公司 用聚乙烯醇作载体聚合物的化合物固体分散体
EP3310354A4 (en) * 2015-06-17 2018-12-12 Dispersol Technologies, LLC Improved formulations of deferasirox and methods of making the same
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
EP4552641A3 (en) * 2016-05-09 2025-07-30 AustinPx, LLC Improved drug formulations
JP7376220B2 (ja) * 2017-09-11 2023-11-08 オースティンピーエックス リミテッド ライアビリティ カンパニー 熱動力学的に溶融ブレンドされるバッチの熱感受性部分用の、直接プローブにより感知した温度による、速度変更のための方法
EP3684371A4 (en) * 2017-09-22 2021-05-19 Dispersol Technologies, LLC PHARMACEUTICAL FORMULATIONS OF ABIRATERONE CYCLIC OLIGOMERS AND METHOD FOR PREPARATION AND ADMINISTRATION THEREOF
CN109663524B (zh) * 2017-10-13 2022-07-15 分散技术有限责任公司 用于热动力学熔体共混批次的热敏部分的速度改变的直接进样探头感测温度方法
SI3470133T1 (sl) 2017-10-13 2021-02-26 Dispersol Technologies, Llc Metoda za spreminjanje hitrosti z neposrednim zaznavanjem temperature s pomočjo sonde za toplotno občutljive dele termokinetično staljene serije mešanic
CN111511365A (zh) * 2017-11-10 2020-08-07 分散技术有限责任公司 改进的药物制剂
EP3492070A1 (en) * 2017-11-30 2019-06-05 BIT Pharma GmbH Process and device for preparing a solid dispersion
WO2019125683A1 (en) * 2017-12-21 2019-06-27 Danisco Us Inc Enzyme-containing, hot-melt granules comprising a thermotolerant desiccant
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
US20220401579A1 (en) * 2019-11-30 2022-12-22 Dispersol Technologies, Llc Inclusion complexes of pharmaceuticals and cyclic oligomers
CA3162315A1 (en) * 2019-12-20 2021-06-24 Marinus Jacobus Verwijs Crystalline hydrobromide salt of a ezh2 inhibitor, its preparation and pharmaceutical composition useful for the treatment of cancer
WO2021202928A1 (en) 2020-04-01 2021-10-07 Board Of Regents, The University Of Texas System Pharmaceutical compositions of niclosamide
US20220175812A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
EP4259143A4 (en) * 2020-12-11 2024-11-13 Board of Regents, The University of Texas System COMPOSITIONS AND METHODS FOR MANUFACTURING COCRYSTALS BY DIELECTRIC HEATING WITH DISPERSIVE AND DISTRIBUTIVE MIXTURE
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
WO2023010030A1 (en) * 2021-07-27 2023-02-02 Board Of Regents, The University Of Texas System Improved drug processing methods to increase drug loading
WO2023034844A1 (en) 2021-08-31 2023-03-09 Board Of Regents, The University Of Texas System Delayed release niclosamide formulation
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
CN119453203A (zh) * 2025-01-09 2025-02-18 山东百农思达生物科技有限公司 一种含杀虫单和阿维菌素的复合微乳制剂及其制备工艺

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161588A (ja) * 2005-12-09 2007-06-28 Kotobuki Seiyaku Kk フェノフィブラートの固体分散体及びこれを含む高脂血症治療剤

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2319478A1 (fr) * 1975-07-30 1977-02-25 Gen Electric Extrudeuse et procede d'extrusion de materiaux thermoplastiques
US4230615A (en) * 1978-11-21 1980-10-28 Carlew Chemicals Limited Process for controlled mixing in a high intensity mixer
US4628073A (en) * 1984-10-03 1986-12-09 Monsanto Company Soft, rubbery, multiphase matrix material and methods for its production
US4789597A (en) * 1987-01-12 1988-12-06 Fetherstonhaugh & Co. Incorporation of chemically reactive agents on resin particles
JP2527107B2 (ja) * 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH07159587A (ja) 1993-12-07 1995-06-23 Hitachi Ltd 樹脂性能モニタ
JPH07187998A (ja) * 1993-12-27 1995-07-25 Kao Corp 錠剤の製造方法
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5895790A (en) * 1995-03-14 1999-04-20 Good; Elmer Thermosetting wide range polymer blends
DE19531067A1 (de) 1995-08-23 1997-02-27 Hermann P T Prof Dr Med Ammon Verwendung von Boswelliasäure und ihren Derivaten zur Hemmung der normalen und gesteigerten Leukozytenelastase- oder Plasminaktivität
KR19990044257A (ko) * 1996-05-20 1999-06-25 디르크 반테 생체이용율이 개선된 항진균성 조성물
US20010053791A1 (en) 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
US6709146B1 (en) 2000-07-28 2004-03-23 David Little Thermokinetic mixer and method of using
NZ529490A (en) 2001-06-22 2005-08-26 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug
KR20040011248A (ko) 2002-07-30 2004-02-05 환인제약 주식회사 암로디핀의 고체분산체와 그 제조방법 및 그를 포함하는약학적 조성물
BRPI0407181A (pt) 2003-02-03 2006-02-07 Novartis Ag Formulação farmacêutica
GB0319797D0 (en) * 2003-08-26 2003-09-24 Leuven K U Res & Dev Particle size reduction of poorly soluble drugs
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
CN100563658C (zh) 2003-11-14 2009-12-02 味之素株式会社 苯丙氨酸衍生物的固体分散体或固体分散体医药制剂
US20050258288A1 (en) 2003-11-26 2005-11-24 E. I. Du Pont De Nemours And Company High pressure media milling system and process of forming particles
JP2005263758A (ja) * 2004-03-22 2005-09-29 Kirin Brewery Co Ltd 非晶質のｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キナゾリニル）オキシ］フェニル｝−ｎ’−プロピルウレア
KR101086254B1 (ko) * 2004-11-04 2011-11-24 에스케이케미칼주식회사 생체이용률이 개선된 프란루카스트 고체분산체 조성물 및그 고체분산체의 제조방법
EP1865929A2 (en) 2005-03-28 2007-12-19 Bioresponse, L.L.C. Diindolylmethane-based compositions and methods of use thereof for promoting oral mucosal and bone health
JP2006347939A (ja) * 2005-06-15 2006-12-28 Tokyo Printing Ink Mfg Co Ltd 薬物高分子複合体の製造方法及び薬物高分子複合体
CA2990445C (en) 2007-08-21 2020-05-05 Board Of Regents, The University Of Texas System Thermo-kinetic mixing for pharmaceutical applications
US9545361B1 (en) * 2011-07-25 2017-01-17 Dispersol Technologies, Llc Multiple speed process for preserving heat sensitive portions of a thermokinetically melt blended batch
JP2012047227A (ja) 2010-08-25 2012-03-08 Nippon Steel & Sumikin Metal Products Co Ltd ナット保持部材
US20140039031A1 (en) 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
WO2016073421A1 (en) 2014-11-03 2016-05-12 Dispersol Technologies, Llc Improved formulations of vemurafenib and methods of making the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007161588A (ja) * 2005-12-09 2007-06-28 Kotobuki Seiyaku Kk フェノフィブラートの固体分散体及びこれを含む高脂血症治療剤

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11246935B2 (en) 2016-05-13 2022-02-15 Merck Patent Gmbh Particle size and distribution of polymer for melt extrusion application

Also Published As

Publication number Publication date
WO2009026461A2 (en) 2009-02-26
JP2014221816A (ja) 2014-11-27
CA2990445C (en) 2020-05-05
CA2697099A1 (en) 2009-02-26
US10022385B2 (en) 2018-07-17
US10668085B2 (en) 2020-06-02
US20090053315A1 (en) 2009-02-26
JP2016121195A (ja) 2016-07-07
US20230172949A1 (en) 2023-06-08
JP6073043B2 (ja) 2017-02-01
US20180360850A1 (en) 2018-12-20
CA3076115C (en) 2022-06-28
US12023343B2 (en) 2024-07-02
WO2009026461A3 (en) 2009-04-30
CN101835492A (zh) 2010-09-15
EP2187968A2 (en) 2010-05-26
US20130303630A1 (en) 2013-11-14
JP2019052173A (ja) 2019-04-04
JP2010536877A (ja) 2010-12-02
CA3076115A1 (en) 2009-02-26
US9339440B2 (en) 2016-05-17
US11439650B2 (en) 2022-09-13
EP2187968A4 (en) 2013-02-20
CA2697099C (en) 2018-02-20
US20160250230A1 (en) 2016-09-01
US20200261473A1 (en) 2020-08-20
US8486423B2 (en) 2013-07-16
CA2990445A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
CN101835492B (zh) 用于制药应用的热动力学混合
Dhaval et al. Twin-screw extruder in pharmaceutical industry: history, working principle, applications, and marketed products: an in-depth review
ES2699075T3 (es) Forma galénica farmacéutica que comprende una composición portadora polimérica
US20160193151A1 (en) Dosage form incorporating an amorphous drug solid solution
JP6491669B2 (ja) Ｃｇｒｐ活性化合物の錠剤製剤
JP6189429B2 (ja) ジエチルアミノエチルメタクリレートコポリマーをベースにした活性成分含有固体分散体
EP4008314A2 (en) Thermo-kinetic mixing for pharmaceutical applications
Patil A review on employing twin screw hot melt extrusion technology for the enhancement of the solubility profile of poorly aqueous-soluble APIs
DiNunzio et al. Polymeric interactions with drugs and excipients
Williams III et al. Thermo-kinetic mixing for pharmaceutical applications
Sandhu et al. Hot‐Melt Extrusion Technology for Modified‐Release (MR) Formulation Development
DiNunzio et al. Melt extrusion: pharmaceutical applications
Narala Novel Formulation Strategies With Hot-Melt Extrusion Technology to Address Physicochemical and Physiological Constraints for Improved Oral Drug Delivery
Hariharaputhraayyanar et al. AN EXTENSIVE REVIEW ON SUBLINGUAL MINITABLET OF RESPIRIDONE AND EVALUATION BY MELT-GRANULATION METHOD
Keen Novel formulations and thermal processes for bioavailability enhancement of soluble and poorly soluble drugs
US20230114357A1 (en) Continuous melt-coating of active pharmaceutical ingredients using surfactants for dissolution enhancement
Patel Dissolution Improvment of a Poorly Soluble Drug Using Hot Melt Extrusion Technique
Bello Physiochemical and drug release properties of Liquisolid formulations in comparison to their physical mixture counterparts
Alshetaili Solubility enhancement, mechanical properties and taste masking of poorly water soluble compounds by optimizing hot melt extrusion processing
PAUL MASTER OF PHARMACY
Dahiya et al. INTERNATIONAL JOURNAL OF INSTITUTIONAL PHARMACY AND LIFE SCIENCES
Singh Design and development of drug delivery systems for immediate and sustained release utilizing hot melt extrusion
rights are reserved by Kharde et al. Formulation and Evaluation of Fast Disintegrating Tablet of Carvedilol

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: DESPAIGNE SPEED TECHNOLOGY LTD.

Free format text: FORMER OWNER: INTEGRATED COMPOSITE MATERIAL CORPORATION

Effective date: 20150422

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20150422

Address after: Texas, USA

Patentee after: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Patentee after: Despain Speed Technology Co.,Ltd.

Address before: Texas, USA

Patentee before: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Patentee before: INTEGRATED COMPOSITE MATERIAL Corp.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: Texas, USA

Patentee after: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Patentee after: Austin Pharmaceutical Co.,Ltd.

Address before: Texas, USA

Patentee before: BOARD OF REGENTS THE University OF TEXAS SYSTEM

Patentee before: Despain Speed Technology Co.,Ltd.